• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    $TXG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $CPNG alert in real time by email

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform

    Separately, Fanatics releases its first environmental, social and governance (ESG) report

    Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising and building some of the world's most influential tech companies and consumer brands.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005104/en/

    Lydia Jett (Photo: Business Wire)

    Lydia Jett (Photo: Business Wire)

    Both well-admired leaders will play vital roles in uncovering and amplifying opportunities for Fanatics to continue scaling its businesses worldwide, which currently include licensed merchandise and e-commerce, trading cards and collectibles, digital collectibles and NFT's, and online sports betting and iGaming.

    "Fanatics is in the midst of incredible transformation and the deep expertise and insight that Lydia and Jonathan both bring to the board will be vital as we unlock a new digital experience for sports fans globally," said Fanatics CEO Michael Rubin. "They are both visionaries in their respective fields that will provide invaluable support and guidance as we continue building a revolutionary sports platform."

    Lydia, the first female to hold the title of Managing Partner within SoftBank's Vision Fund, has nearly twenty years of experience investing in and serving on the boards of market leading technology businesses. Since SoftBank's initial backing of Fanatics in 2017 - when the firm led a more than $1 billion investment round - she has been a driving force behind the company's innovation across the licensed sports industry and recent expansion beyond merchandise.

    "Over my past five years with the Fanatics management team, I have seen an extraordinary focus, agility and creativity targeted towards fundamentally remaking an industry to better serve its ultimate customers: leagues, athletes and fans," said Jett. "As we enter the next half decade together, Fanatics is better positioned than ever to be a driving force behind improving a global sports fan's experience across the digital and physical world."

    Jonathan, a globally respected marketing and advertising professional, co-founded the influential brand building and marketing consultancy firm, TwentyFirstCenturyBrand, and serves as Executive Chairman. Mildenhall also previously served as CMO of Airbnb from 2014 to 2018, a time in which the company's valuation increased from $1 billion to more than $31 billion. Mildenhall's expertise is defining company purpose and values, brand strategy and digital transformation, assets that will be invaluable to Fanatics as the company continues to build its brand globally and unlock opportunities to engage with sports fans across current and emerging verticals.

    "Over the last six months I have gotten to know Michael, his executive team, and the Fanatics business in a deep and substantial way," said Mildenhall. "The deeper my understanding of the incredible opportunity ahead the more irresistible the idea of joining the board became. Fanatics will become a culturally significant global brand that will define this and further generations to come."

    In addition to Fanatics, both Lydia and Jonathan serve as members on several company boards. Jett has represented SoftBank on the boards of global internet, e-commerce and blockchain companies including Coupang (NYSE:CPNG), Flipkart, GoTo (IDX: GOTO) and Weee!, and Mildenhall serves on the board of Peloton, Northern Star SPAC, and GoFundMe.

    Separate from these board appointments, Fanatics recently released its first environmental, social and governance (ESG) report. The report, which spans 2020 and 2021, covers ESG efforts across several initiatives, including the company's customer-centric approach, philanthropic endeavours, Fanatics' inclusion, diversity, equity, and advocacy (IDEA) model, sustainability, labor and human rights, and much more.

    To read the full report: https://www.fanaticsinc.com/global-impact

    About Lydia Jett

    Lydia Jett is a Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA) where she has led and represented SoftBank on the Board of Directors of many of the firm's global investments in consumer internet, e-commerce and blockchain companies including: Coupang (NYSE:CPNG), Fanatics, Flipkart, GoTo (IDX: GoTo), LTK, Misfits Market, Pacaso, The Sandbox, Veho and Weee!

    Prior to SBIA, Lydia was a senior member of the investment team at SoftBank Group Corp International where she led SBGI's investments in Guardant Health (NASDAQ:GH) and 10X Genomics (NASDAQ:TXG). Previously, Lydia was a Vice President at M/C Partners, a growth equity firm, and an Associate at Goldman Sachs in the Principal Investment Area where she invested across media and technology sectors. She started her career at JPMorgan.

    In addition, Lydia is an independent board member of Ozon (NASDAQ:OZON), where she serves on the Audit, Compensation and Nomination and Governance Committees and has published work in Fast Company. Lydia is a graduate of the Stanford Graduate School of Business, the London School of Economics and Smith College, and has been recognized as one of Fortune's "Most Powerful Women."

    About Jonathan Mildenhall

    Jonathan Mildenhall co-founded TwentyFirstCenturyBrand, the influential brand-building and marketing consultancy firm, in 2018, and serves as the company's Executive Chairman. He is also a board member on several company boards, including Peloton, Northern Star SPAC, and GoFundMe, and he serves as the Co-Chair of non-profit College Track's Los Angeles Advisory Board. Prior to co-founding TwentyFirstCenturyBrand, Mildenhall served as CMO of Airbnb from 2014 to 2018, during which time Airbnb's valuation increased from $1 billion to more than $31 billion.

    Prior to Airbnb, Mildenhall led The Coca-Cola Company's marketing initiatives as VP of global advertising strategy and content excellence from 2007 to 2013, and as SVP of integrated marketing communication and design excellence from 2013 to 2014. Earlier in his career, Mildenhall served in various management positions in advertising. Mildenhall holds an HND in Business and Finance from The Manchester Metropolitan University. He completed the Advanced Management Program at Harvard Business School and holds an Honorary Doctorate in Business Administration from The Manchester Metropolitan University. Mildenhall lives in Los Angeles with his husband Mirco and their children Dominica and Oliver.

    He has been named to the Financial Times "EMpower 100 Ethnic Minority Leaders" list, has won the AdWeek Brand Genius award, and has been recognized on the Business Insider list of the "Top 50 Most Innovative CMOs in the World."

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005104/en/

    Get the next $CPNG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPNG
    $GH
    $OZON
    $TXG

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    4/10/2025$55.00Outperform
    Mizuho
    Coupang Inc.
    $CPNG
    2/26/2025$28.50Hold → Buy
    Deutsche Bank
    10x Genomics Inc.
    $TXG
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    Guardant Health Inc.
    $GH
    1/23/2025$60.00Overweight
    Barclays
    Coupang Inc.
    $CPNG
    10/7/2024$30.00Underperform → Outperform
    Bernstein
    Coupang Inc.
    $CPNG
    9/4/2024$18.00 → $31.00Hold → Outperform
    CLSA
    10x Genomics Inc.
    $TXG
    9/3/2024$35.00Outperform
    Leerink Partners
    10x Genomics Inc.
    $TXG
    7/22/2024$24.00Hold → Buy
    Jefferies
    More analyst ratings

    $CPNG
    $GH
    $OZON
    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recomm

      6/10/25 7:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

      LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in a patient's blood without the need for a tissue sample. The LIBERATE study retrospectively analyzed 29

      6/9/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide for more effective treatment or diagnosis of life-threateni

      6/3/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Guardant Health with a new price target

      Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

      4/10/25 12:41:47 PM ET
      $GH
      Medical Specialities
      Health Care
    • Coupang upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Coupang from Hold to Buy and set a new price target of $28.50

      2/26/25 7:03:12 AM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • 10x Genomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

      2/13/25 7:11:34 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CPNG
    $GH
    $OZON
    $TXG
    Financials

    Live finance-specific insights

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Coupang Announces Results for First Quarter 2025

      Net Revenues of $7.9 billion, up 11% YoY and 21% on an FX-neutral basis Gross Profit of $2.3 billion, up 20% YoY and 31% on an FX-neutral basis Operating income of $154 million, up $114 million Operating Cash Flow of $2.0 billion and Free Cash Flow of $1.0 billion for the trailing twelve months Coupang, Inc. (NYSE:CPNG) today announced financial results for its first quarter ended March 31, 2025. Q1 2025 Consolidated Highlights: Net revenues were $7.9 billion, up 11% YoY on a reported basis and 21% YoY on an FX-neutral basis. Gross profit increased 20% YoY and 31% YoY on an FX-neutral basis to $2.3 billion. Gross profit margin was 29.3%, an improvement of 217 bps YoY. Operating i

      5/6/25 4:05:00 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

      4/30/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    Leadership Updates

    Live Leadership Updates

    See more
    • Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

      Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

      3/5/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • Roberto A. Mignone Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

      10/24/24 5:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • 10x Genomics Announces Senior Leadership Changes

      PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

      8/8/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CPNG
    $GH
    $OZON
    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/13/24 7:34:17 PM ET
      $GH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coupang Inc.

      SC 13G/A - Coupang, Inc. (0001834584) (Subject)

      11/12/24 4:30:29 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Coupang Inc.

      SC 13G/A - Coupang, Inc. (0001834584) (Subject)

      11/8/24 2:52:10 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Svf Investments (Uk) Ltd sold $282,500,000 worth of shares (10,000,000 units at $28.25) (SEC Form 4)

      4 - Coupang, Inc. (0001834584) (Issuer)

      6/17/25 9:00:05 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chief Legal Officer Saia John G. covered exercise/tax liability with 535 shares and converted options into 1,020 shares, increasing direct ownership by 1% to 43,568 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      6/16/25 8:05:45 PM ET
      $GH
      Medical Specialities
      Health Care
    • Chief Information Officer Kalia Kumud converted options into 637 shares and covered exercise/tax liability with 228 shares, increasing direct ownership by 2% to 19,174 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      6/16/25 8:04:24 PM ET
      $GH
      Medical Specialities
      Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 30, 2024 - FDA Roundup: July 30, 2024

      For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

      7/30/24 3:38:18 PM ET
      $GH
      Medical Specialities
      Health Care
    • May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

      For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

      5/28/21 1:05:48 PM ET
      $AMGN
      $GH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
    • May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

      For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

      5/21/21 12:50:51 PM ET
      $JNJ
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $CPNG
    $GH
    $OZON
    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Greenoaks Capital Partners Llc bought $37,540,910 worth of Class A Common Shares (1,400,000 units at $26.81) (SEC Form 4)

      4 - Coupang, Inc. (0001834584) (Issuer)

      5/16/25 7:30:26 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Greenoaks Capital Partners Llc bought $54,632,027 worth of Class A Common Shares (2,250,199 units at $24.28) (SEC Form 4)

      4 - Coupang, Inc. (0001834584) (Issuer)

      11/12/24 9:15:38 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    SEC Filings

    See more
    • SEC Form 144 filed by Guardant Health Inc.

      144 - Guardant Health, Inc. (0001576280) (Subject)

      6/18/25 5:00:29 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Guardant Health Inc.

      144 - Guardant Health, Inc. (0001576280) (Subject)

      6/17/25 4:01:58 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Guardant Health Inc.

      144 - Guardant Health, Inc. (0001576280) (Subject)

      6/16/25 4:20:52 PM ET
      $GH
      Medical Specialities
      Health Care